Cipla’s chief executive Subhanu Saxena is leaving the India-based generics maker at the end of this month amid a shake-up in the company’s operations.
Saxena has been at the helm of Cipla since 2013, moving to the Indian drugmaker after a 14-year spell at Novartis, but is now leaving to handle emerging “family priorities,” according to the company.
He will be replaced by Umang Vohra, currently the company’s global chief financial and strategy officer, who joined the company last October from Dr Reddy’s Laboratories. Cipla also cemented ties with the family of longtime backer and non-executive chairman Y. K. Hamied by promoting his niece–Samina Vaziralli–to the role of executive vice chairman.
“Having been aware of his personal circumstances, we respect Subhanu’s decision to leave Cipla,” said Hamied, adding that he was “delighted to see two young leaders … take on higher responsibilities” within the company.
Last year, Cipla embarked on a major restructuring aimed at cutting costs and improving profitability. It bailed out of some smaller international markets to focus on key growth territories, particularly the U.S., where it is viewed as a late mover compared to its peers, as well as South Africa.
On Saxena’s watch, Cipla closed a deal to acquire its first U.S.-based manufacturing facility, buying generic drugmaker InvaGen Pharmaceuticals in a deal valued at $550 million, and also made an $89 million investment in a South African biosimilars plant. Earlier this year, Saxena also formed a new executive council to simplify decisionmaking at the group.
Saxena’s departure comes as Cipla posted a 6% decline in revenues–with a 21% fall in North America–as well as a 42% drop in earnings before interest, tax, depreciation and amortization (EBIDTA).
The performance was put down to challenging conditions in the domestic market and an increased spend on R&D as it prepares for new product launches. U.S. sales were hit by lower sales of a generic version of AstraZeneca’s gastrointestinal drug Nexium to Teva, after the latter’s first-to-file market exclusivity lapsed.
Meanwhile, Cipla’s Indian business has been affected by a government ban on more than 300 fixed-dose combination medicines, which took effect in March, on the grounds they had no “therapeutic justification.” The ban also affected products from Pfizer, Procter & Gamble and Glenmark, among others, but is currently being challenged in the courts.
Brokerage firm Systematix Institutional Equities said the second quarter been challenging for Indian pharmaceutical firms thanks to “regulatory headwinds in key markets, volatility in oil-linked products and sharp depreciation in currencies in certain emerging markets,” according to a Nikkei Asian Review article.
That sentiment was echoed by analysts at RBC Capital Markets which said that other Indian generic drugmakers–including Sun Pharma and Dr Reddy’s–have also been suffering from “US pricing erosion.”
By Phil Taylor
Source: Fierce Pharma
The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.
US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.
EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.